Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Hida

Showing results (161-170 of 171) with videos related to

Pageof 18
Sort By:
Oncogene|January 27, 2010
Osteopontin-mediated enhanced hyaluronan binding induces multidrug resistance in mesothelioma cellsK Tajima, R Ohashi, Y Sekido, et al.
Nihon Shokakibyo Gakkai Zasshi = the Japanese Journal of Gastro-Enterology|October 1, 1982
[Esophageal achalasia associated with superficial spreading type of early esophageal cancer--report of a case]S Tanaka, E Okamoto, K Kuwata, et al.
Human Genetics|October 6, 1998
Japanese juvenile retinoschisis is caused by mutations of the XLRS1 geneY Hotta, K Fujiki, M Hayakawa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 23, 2015
Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumorsM G Kris, D R Camidge, G Giaccone, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 10, 2013
Time to first cigarette and lung cancer risk in JapanH Ito, S Gallus, S Hosono, et al.
Oncogene|July 21, 2001
Genetic alteration of the beta-catenin gene (CTNNB1) in human lung cancer and malignant mesothelioma and identification of a new 3p21.3 homozygous deletionK Shigemitsu, Y Sekido, N Usami, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2015
Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study)K Takeuchi, Y Togashi, Y Kamihara, et al.
Lung Cancer (Amsterdam, Netherlands)|July 20, 2019
Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: The global, multicenter EXPRESS studyM Dietel, N Savelov, R Salanova, et al.
European Journal of Cancer (Oxford, England : 1990)|December 19, 2018
Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK studyJ von Pawel, R Bordoni, M Satouchi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 17, 2021
Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancerS Sugawara, J-S Lee, J-H Kang, et al.
Pageof 18

Showing results (161-170 of 171) with videos related to

Sort By:
Pageof 18
Oncogene|January 27, 2010
Osteopontin-mediated enhanced hyaluronan binding induces multidrug resistance in mesothelioma cellsK Tajima, R Ohashi, Y Sekido, et al.
Nihon Shokakibyo Gakkai Zasshi = the Japanese Journal of Gastro-Enterology|October 1, 1982
[Esophageal achalasia associated with superficial spreading type of early esophageal cancer--report of a case]S Tanaka, E Okamoto, K Kuwata, et al.
Human Genetics|October 6, 1998
Japanese juvenile retinoschisis is caused by mutations of the XLRS1 geneY Hotta, K Fujiki, M Hayakawa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 23, 2015
Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumorsM G Kris, D R Camidge, G Giaccone, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 10, 2013
Time to first cigarette and lung cancer risk in JapanH Ito, S Gallus, S Hosono, et al.
Oncogene|July 21, 2001
Genetic alteration of the beta-catenin gene (CTNNB1) in human lung cancer and malignant mesothelioma and identification of a new 3p21.3 homozygous deletionK Shigemitsu, Y Sekido, N Usami, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2015
Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study)K Takeuchi, Y Togashi, Y Kamihara, et al.
Lung Cancer (Amsterdam, Netherlands)|July 20, 2019
Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: The global, multicenter EXPRESS studyM Dietel, N Savelov, R Salanova, et al.
European Journal of Cancer (Oxford, England : 1990)|December 19, 2018
Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK studyJ von Pawel, R Bordoni, M Satouchi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 17, 2021
Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancerS Sugawara, J-S Lee, J-H Kang, et al.
Pageof 18